NR6A1 and prostate carcinoma: Recently, NR6A1 could serve as a biomarker of disease progression and aggressiveness for prostate cancer (PCa), which showed that increased NR6A1 immunoreactivity was remarkably related to advanced T-stage and cancer cell growth26.